Skip to main content

Shanmugam Muthusamy's Form 4 filing

Ani Pharmaceuticals Inc (ANIP) · filed Dec 19, 2023

Accession no.
0001870913-23-000020
Filed
Dec 19, 2023
Trade date
Dec 15-19, 2023
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions. Open-market sales total $2.63M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Shanmugam MuthusamyCIK 0001870913Director, Officer (HEAD OF R&D, COO-NOVITIUM OPS)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 15, 2023Common StockSSaleDisposed−11,974$52.44F2−$627,916.56970,646Indirect
Dec 18, 2023Common StockSSaleDisposed−13,026$52.44F4−$683,083.44957,620Indirect
Dec 19, 2023Common StockSSaleDisposed−25,000$52.65F5−$1,316,250932,620Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $51.97 to $52.97, inclusive.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $52.02 to $52.97, inclusive.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $52.45 to $53.19, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)